10-K: Turnstone Biologics Outlines Share Structure and Development Pipeline in 10-K Filing

Turnstone Biologics' 10-K filing details its common stock structure, ongoing clinical trials for its Selected TIL therapies, and future development plans.

Summary

• Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies, particularly for solid tumors.
• The company's lead product candidate, TIDAL-01, is undergoing Phase 1 clinical trials for breast, colorectal, head and neck cancers, and uveal melanoma, with initial clinical updates expected in mid-2024.
• Turnstone is also advancing its preclinical pipeline, including TIDAL-02, a next-generation Selected TIL program, and a combination program of TIDAL-01 with viral immunotherapy.
• The company's approach involves selecting and expanding the most potent tumor-reactive T cells, aiming for a higher proportion of these cells in their TIL products compared to traditional bulk TIL therapies.
• Turnstone's Selected TIL approach has achieved tumor-reactive T cell frequencies of up to 62%, with a median of 23%, and is targeting >70% in future drug products.
• The company has raised $449.8 million in capital since its inception, including $80 million from its IPO in July 2023 and $7.8 million from the exercise of the underwriters option to purchase additional shares.
• Turnstone is also exploring strategic partnerships and collaborations to maximize the potential of its programs, including a strategic alliance with Moffitt Cancer Center.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of the company's technology and the significant risks and challenges it faces. While the technology is promising, the company's financial situation and the inherent uncertainties of drug development temper the overall sentiment.

Positives

• The company is pioneering a differentiated approach to TIL therapy, focusing on selecting and expanding the most potent tumor-reactive T cells.
• Turnstone has achieved high frequencies of tumor-reactive T cells in its Selected TIL products, with a median of 23% and targeting >70% in future products.
• The company has multiple ongoing Phase 1 clinical trials for its lead product candidate, TIDAL-01, with initial clinical updates expected in mid-2024.
• Turnstone is actively advancing its preclinical pipeline, including TIDAL-02 and a combination program of TIDAL-01 with viral immunotherapy.
• The company has a strong leadership team with extensive experience in biologics, drug discovery, and development.
• Turnstone has established strategic partnerships and collaborations with academic institutions, including Moffitt Cancer Center.

Negatives

• The company has a limited operating history and has incurred substantial net losses since its inception.
• Turnstone has no products approved for commercial sale and has not generated any revenue from product sales.
• The company's business is highly dependent on the success of its lead product candidate, TIDAL-01, and other current and future product candidates.
• Clinical development involves a lengthy and expensive process with uncertain outcomes.
• The manufacture of the company's product candidates is complex and may encounter difficulties in production and scaling-up.
• The company faces significant competition from other pharmaceutical and biotechnology companies.

Risks

• The company has limited operating history, has incurred substantial net losses and anticipates that it will continue to incur net losses for the foreseeable future.
• Turnstone will require additional capital to fund its operations, and if it fails to obtain necessary capital on acceptable terms, or at all, it will not be able to complete the development and future commercialization of its current and any future product candidates.
• The company's business is highly dependent on the success of its lead Selected TIL product candidate TIDAL-01, as well as its other current and any future product candidates.
• Clinical development involves a lengthy and expensive process, with uncertain outcomes.
• The manufacture of the company's product candidates is complex, and the company may encounter difficulties in production, particularly with respect to process development, quality control, or scaling-up of any future manufacturing capabilities.
• The company faces significant competition and if it fails to compete effectively, its business, results of operations and financial condition could be adversely affected.
• Negative developments in the fields of immuno-oncology and TIL-based immunotherapy could damage public perception of the company's product candidates and adversely affect its business, results of operations and financial condition.
• The company has relied and expects to continue to rely on third parties to conduct certain aspects of its preclinical studies, to conduct its clinical trials and to conduct investigator sponsored clinical trials of its product candidates.
• The regulatory approval process for the company's product candidates in the United States, and other jurisdictions is currently uncertain and will be lengthy, time-consuming and inherently unpredictable.
• The company's success depends in part on its ability to protect its intellectual property.
• Sales of a substantial number of shares of the company's common stock in the public market could cause its stock price to fall.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future as it continues its research and development activities and seeks regulatory approvals for its product candidates. The company plans to fund future operations through equity and debt financings, licensing transactions, and collaborations or strategic partnerships.

Management Comments

• The company believes the most significant challenge to creating curative immunotherapies in these patients is the low numbers of T cells that can recognize and attack the tumor, which we refer to as tumor-reactive T cells.
• The company believes that increasing the proportion and diversity of tumor-reactive T cells in a TIL product can expand the potential utility of TILs, if approved, to a greater breadth of tumor types, where bulk TILs have shown limited to no objective responses in clinical trials to date.

Industry Context

The document highlights the limitations of current immunotherapies, such as immune checkpoint inhibitors, and the potential of TIL therapy to address these limitations. It also notes the growing interest in cell therapies, including CAR-T and TCR-T, for solid tumors, positioning Turnstone's Selected TIL approach as a differentiated strategy.

Comparison to Industry Standards

• The document compares Turnstone's Selected TIL approach to standard bulk TIL therapies, noting that bulk TILs have shown objective responses in clinical trials in limited solid tumor types, with the greatest success observed in metastatic melanoma.
• The document cites studies showing that bulk TIL monotherapy has yielded objective response rates of approximately 30% to 50% in metastatic melanoma patients refractory to ICI therapy, with complete response rates ranging from approximately 5% up to 20%.
• The document also references academic studies using rudimentary selection strategies for tumor-reactive T cells, reporting responses including tumor regressions in a single patient bile duct study, a single patient colorectal cancer study, one complete response and two partial responses out of six patients in a breast cancer study, and two complete responses and one partial response out of seven patients in a non-small cell lung cancer study.
• The document notes that bulk TILs have demonstrated limited to no objective responses in clinical trials in more than 50 patients with epithelial malignancies and low TMB tumors studied at the National Cancer Institute.
• The document positions Turnstone's Selected TIL approach as a next-generation therapy that overcomes the limitations of bulk TILs by selecting and expanding the most potent tumor-reactive T cells.

Stakeholder Impact

• Shareholders face the risk of potential losses due to the company's ongoing net losses and the volatility of its stock price.
• Employees may be affected by potential workforce reductions or restructuring activities if the company is unable to secure additional funding.
• Patients may benefit from the development of new and effective cancer therapies, but the success of these therapies is not guaranteed.
• The company's suppliers and contract manufacturers may be affected by the company's financial performance and ability to secure additional funding.

Next Steps

• The company intends to provide an initial clinical update across its three ongoing Phase 1 clinical trials for TIDAL-01 in mid-2024.
• The company plans to continue advancing its preclinical pipeline programs, including TIDAL-02 and the combination program of TIDAL-01 with viral immunotherapy.
• The company will continue to explore strategic partnerships and collaborations to maximize the potential of its programs.

Key Dates

Keywords

TIL therapy, Selected TILs, immunotherapy, solid tumors, TIDAL-01, TIDAL-02, cancer treatment, clinical trials, biotechnology, oncology